Development of insulin antibodies and changes in titers over a long-term period in patients with type 2 diabetes

被引:27
作者
Hattori, Naoki [1 ]
Duhita, Maharani Retna [1 ]
Mukai, Akira
Matsueda, Megumi
Shimatsu, Akira [2 ]
机构
[1] Ritsumeikan Univ, Dept Pharmaceut Sci, Kusatsu, Shiga 5258577, Japan
[2] Natl Hosp Org, Kyoto Med Ctr, Clin Res Inst, Kyoto, Japan
关键词
Type; 2; diabetes; Insulin antibodies; Glargine; Detemir; Lispro; Aspart; NPH INSULIN; AUTOIMMUNE SYNDROME; GLUCOSE CONTROL; ASPART; HYPOGLYCEMIA; ANALOG; GLARGINE; THERAPY; LISPRO; TRIAL;
D O I
10.1016/j.cca.2014.03.008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
100118 [医学信息学]; 100208 [临床检验诊断学];
摘要
Background: Recently, insulin analogs have become widely used for the treatment of diabetes. The aim of this study was to determine differences in the antigenicity of insulin analogs and long-term changes in titers in patients with type 2 diabetes. Methods: Insulin antibodies were examined using polyethylene glycol and protein G methods in 381 patients with type 2 diabetes. Results: Insulin antibodies were detected in 48 of 118 patients (40.7%) who used insulin, and insulin glargine and aspart were more antigenic. Insulin antibodies were unexpectedly found in seven of 263 patients (2.7%) who had never used insulin. Serum insulin concentrations in patients with insulin antibodies were significantly higher than those without them. Two years after the initial evaluation, insulin antibodies were still positive in 92.7% of patients who used insulin; while, they disappeared in all patients who had never used insulin. A patient who stopped insulin injections 6 years ago was found to be positive for insulin antibodies at the first evaluation as well as 2 years later. Conclusions: Insulin glargine and aspart induced insulin antibodies more frequently, and insulin antibodies remained in patients for a long time. Insulin antibodies should be suspected even in patients not currently on insulin therapy. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:135 / 138
页数:4
相关论文
共 23 条
[1]
Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial [J].
Bartley, P. C. ;
Bogoev, M. ;
Larsen, J. ;
Philotheou, A. .
DIABETIC MEDICINE, 2008, 25 (04) :442-449
[2]
Insulin lispro: Its role in the treatment of diabetes mellitus [J].
Campbell, RK ;
Campbell, LK ;
White, JR .
ANNALS OF PHARMACOTHERAPY, 1996, 30 (11) :1263-1271
[3]
Hypoglycaemia due to insulin autoimmune syndrome: report of two cases with characterisation of HLA alleles and insulin autoantibodies [J].
Cavaco, B ;
Uchigata, Y ;
Porto, T ;
Amparo-Santos, M ;
Sobrinho, L ;
Leite, V .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (03) :311-316
[4]
CHANCE RE, 1976, ACTA ENDOCRINOL-COP, V83, P185
[5]
Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin [J].
Fineberg, NS ;
Fineberg, SE ;
Anderson, JH ;
Birkett, MA ;
Gibson, RG ;
Hufferd, S .
DIABETES, 1996, 45 (12) :1750-1754
[6]
Immunological responses to exogenous insulin [J].
Fineberg, S. Edwin ;
Kawabata, Thomas T. ;
Finco-Kent, Deborah ;
Fountaine, Robert J. ;
Finch, Gregory L. ;
Krasner, Alan S. .
ENDOCRINE REVIEWS, 2007, 28 (06) :625-652
[7]
Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers [J].
Hattori, Naoki ;
Ishihara, Takashi ;
Saiki, Yasuhiko .
CLINICAL ENDOCRINOLOGY, 2009, 71 (05) :702-708
[8]
Comparison of the soluble basal insulin analog insulin detemir with NPH insulin - A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy [J].
Hermansen, K ;
Madsbad, S ;
Perrild, H ;
Kristensen, A ;
Axelsen, M .
DIABETES CARE, 2001, 24 (02) :296-301
[9]
INSULIN AUTOIMMUNE SYNDROME IN JAPAN [J].
HIRATA, Y ;
UCHIGATA, Y .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1994, 24 :S153-S157
[10]
Antibody response to insulin in children and adolescents with newly diagnosed Type 1 diabetes [J].
Holmberg, H. ;
Mersebach, H. ;
Kanc, K. ;
Ludvigsson, J. .
DIABETIC MEDICINE, 2008, 25 (07) :792-797